Intro

This chapter provides an update on FDA drug approvals from December 2020, highlighting pralcetinib's expanded use for RET-mutated medullary thyroid cancer and its significance as a dual inhibitor. Additionally, the approval of margituximab for HER2-positive metastatic breast cancer treatment is discussed, along with its implications for clinical practice.